Suppr超能文献

筛查。

Screening.

机构信息

A.M. & A. Migliavacca Center for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli and Regina Elena, University of Milan, Milan, Italy.

出版信息

Hepatol Res. 2007 Sep;37 Suppl 2:S146-51. doi: 10.1111/j.1872-034X.2007.00179.x.

Abstract

Screening is the only practical approach for improving the management of hepatocellular carcinoma (HCC) patients, as early detection increases the application of curative treatments. A conference of experts from Japan, USA, and Europe (Barcelona 2005) advised surveillance every six months for patients with chronic liver disease at increased risk of HCC with abdominal US. Whether this approach benefits HCC patients in terms of survival is still uncertain, since available data are retrospective and biased by lead-time factors in the calculation of patient survival. Only one randomized controlled study in China showed the benefit of surveillance for HCC; however, in a population-based setting. Today, clinic-based, randomized studies are unfeasible for ethical reasons. In a cohort of 447 Italian patients with compensated cirrhosis, we compared the survival of HCC patients identified along three consecutive quinquennia of surveillance. HCC developed in 112 patients (3.4% per year) and was the prime cause of death. Forty-six patients (41%) had a single tumor with mean sizes of 3.7, 3.0, and 2.2 cm in the three quinquennia (first vs third, P = 0.0147; second vs third, P = 0.02) and 38(44%) underwent radical therapies. Mortality rates in HCC patients fell from 45% in the first quinquennium to 10% in the third (P = 0.0009), in parallel with a reduction in mortality of treated patients (34, 28, and 5%) (first vs third, P = 0.0024). Cirrhotic patients developing HCC during the last five years of surveillance survived longer than previously, as a consequence of improved management of the tumor and complications of cirrhosis. It remains controversial whether HCC screening is cost-effective, i.e. whether the cost of detection, confirmatory studies, and treatment are outbalanced by the number of life-years gained. In a retrospective study of Italian patients with cirrhosis, there was an incremental cost-efficacy ratio of surveillance vs no surveillance to be $USD 112 993 per liver-year saved. The cost of surveillance was increased by surgery applied to 15 patients with HCC detected during surveillance.

摘要

筛查是改善肝细胞癌(HCC)患者管理的唯一实用方法,因为早期发现增加了治愈治疗的应用。来自日本、美国和欧洲(巴塞罗那 2005 年)的专家会议建议,对于患有慢性肝病且 HCC 风险增加的患者,每 6 个月进行腹部超声检查。这种方法是否对 HCC 患者的生存有益仍然不确定,因为现有数据是回顾性的,并且在计算患者生存时受到领先时间因素的影响。只有中国的一项随机对照研究表明 HCC 监测有益;然而,这是在人群基础上进行的。如今,由于伦理原因,基于临床的随机研究是不可行的。在一项 447 名意大利代偿性肝硬化患者的队列研究中,我们比较了连续三个五年监测期间发现的 HCC 患者的生存情况。112 名患者(每年 3.4%)发生 HCC,是死亡的主要原因。46 名患者(41%)有单个肿瘤,在三个五年期的平均大小分别为 3.7、3.0 和 2.2cm(第一 vs 第三,P=0.0147;第二 vs 第三,P=0.02),38 名患者(44%)接受了根治性治疗。HCC 患者的死亡率从第一个五年期的 45%下降到第三个五年期的 10%(P=0.0009),同时接受治疗的患者的死亡率也下降(34、28 和 5%)(第一 vs 第三,P=0.0024)。在监测的最后五年中发生 HCC 的肝硬化患者的生存期比以前更长,这是由于对肿瘤和肝硬化并发症的管理得到改善。HCC 筛查是否具有成本效益,即检测、确认研究和治疗的成本是否超过了获得的生命年数,这仍然存在争议。在一项对意大利肝硬化患者的回顾性研究中,监测与不监测相比,每挽救一个肝年的增量成本效益比为 112993 美元。监测的成本因在监测期间发现的 15 名 HCC 患者接受手术而增加。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验